| Unique ID issued by UMIN | UMIN000063686 |
|---|---|
| Receipt number | R000072890 |
| Scientific Title | A prospective observational study on the efficacy and safety of preemptive treatment (prodrome therapy) using rimegepant during the prodromal phase of migraine |
| Date of disclosure of the study information | 2026/11/18 |
| Last modified on | 2026/11/18 23:35:18 |
Preemptive treatment of migraine attacks using rimegepant during the prodrome
Rimegepant Prodrome Study
A prospective observational study on the efficacy and safety of preemptive treatment (prodrome therapy) using rimegepant during the prodromal phase of migraine
Prodromal Rimegepant Trial
| Japan |
migraine
| Neurology | Neurosurgery |
Others
NO
The objective of this study is to prospectively observe and evaluate the efficacy and safety of preemptive treatment (prodrome therapy) using the oral CGRP receptor antagonist rimegepant (75mg) during the prodromal phase prior to headache onset in real-world clinical practice.
Safety,Efficacy
Inhibition rate of moderate or severe headache within 24 hours after administration of rimegepant (75mg)
1. Inhibition rate of moderate or severe headache within 48 hours.
2. Pain-free rate at 24 hours.
3. Recovery rate of daily functional activities at 24 hours.
4. Incidence and severity of adverse events.
Observational
| 18 | years-old | <= |
| Not applicable |
Male and Female
1. Patients aged 18 years or older diagnosed with migraine based on ICHD-3.
2. Patients who can clearly recognize prodromal symptoms.
3. Patients predicting >75% probability of headache onset within 1-6 hours after prodrome.
4. Patients whose prodromal treatment with rimegepant was decided by the attending physician.
5. Written informed consent obtained.
1. Pregnant, possibly pregnant, or lactating women.
2. Hypersensitivity to rimegepant.
3. Severe psychiatric symptoms.
4. Ineligible as judged by the investigator.
50
| 1st name | Taisyoku |
| Middle name | |
| Last name | Kaku |
Kaku Neurosurgery Clinic
Department of Neurosurgery
753-0066
8-17 Izumi-cho, Yamaguchi-shi, Yamaguchi, 753-0066, Japan
083-920-1001
kakutaisyoku@gmail.com
| 1st name | Taisyoku |
| Middle name | |
| Last name | Kaku |
Kaku Neurosurgery Clinic
Department of Neurosurgery
753-0066
8-17 Izumi-cho, Yamaguchi-shi, Yamaguchi, 753-0066, Japan
083-920-1001
kakutaisyoku@gmail.com
others
others
Other
nstitutional Review Board for Clinical Research, Tokai University School of Medicine
143 Shimokasuya, Isehara-shi, Kanagawa 259-1193, Japan
0463-93-1121
tokai-rec@tokai.ac.jp
NO
| 2026 | Year | 11 | Month | 18 | Day |
Unpublished
Preinitiation
| 2026 | Year | 10 | Month | 08 | Day |
| 2026 | Year | 11 | Month | 01 | Day |
| 2028 | Year | 04 | Month | 30 | Day |
This study is a single-center, prospective observational study evaluating the efficacy and safety of preemptive treatment (prodrome therapy) using rimegepant (75 mg) during the prodromal phase of migraine in real-world clinical practice.
[Details of Observation]
1. Observational Design and Data Collection:
Targeting migraine patients whose
| 2026 | Year | 11 | Month | 18 | Day |
| 2026 | Year | 11 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072890